Roche receives FDA 510(k) clearance for cobas® eplex respiratory pathogen panel 3, enabling labs to customize respiratory testing for local patient needs

Roche Diagnostics announced FDA 510(k) clearance for its new cobas® eplex respiratory pathogen panel 3 (RP3), which detects up to 19 viral and bacterial targets from a single sample, including the newly added Bordetella pertussis. The panel offers up to five customizable configurations based on local disease prevalence and patient needs, with less than one minute of hands-on time and results available in under two hours.

Biognosys Launches Industrialized Discovery to Deliver Scalable, AI-ready Proteomics with Exceptional Cost Efficiency

Biognosys Group, a fully owned affiliate of Bruker Corporation, today announced the launch of Industrialized Discovery.

One Year After Launch, Plasmidsaurus RNA-Seq Challenges RT-qPCR as the Standard for Routine Gene Expression Analysis

One year after launching its ultrafast RNA-Seq service, Plasmidsaurus has reached more than 9,000 researchers across 1,000+ institutions, processing hundreds of thousands of samples to date.

Bioscope.ai Advances Personalized Longevity Medicine Through New Partnerships and Platform Growth

Lab Thread launches new AI tools and strengthens platform with universal AI assistant compatibility

• New MCP server connects external AI tools directly to structured laboratory data, with no exports or custom integrations required • Suite of AI functions address key data bottlenecks in biological research labs, from protocol writing to equipment set-up • The launch also marks Lab Thread's incorporation in the United States, extending support for the company's growing base of US life sciences customers

Lilly Brings FDA-Approved GLP-1 Treatments to Hims & Hers Digital Platform

Lilly and Hims & Hers have partnered to expand access to FDA-approved Zepbound and Foundayo through telehealth. Monthly self-pay prices start at $299 for Zepbound and $149 for Foundayo.

Qureight’s fibrosis imaging biomarker selected by Contineum Therapeutics as a secondary endpoint in Phase 2 PROPEL-IPF clinical trial

Qureight and Contineum Therapeutics, Inc. (Contineum) today announced that Qureight’s Fibr8™ quantitative imaging biomarker is being used as a secondary endpoint in Contineum’s PROPEL-IPF Phase 2 clinical trial examining the safety and efficacy of PIPE-791, Contineum’s lead drug candidate, in idiopathic pulmonary fibrosis (IPF) patients.

Thermo Fisher Scientific Introduces Value-Priced Thermo Scientific™ AmpSure™ Universal qPCR Master Mixes Without Compromising Performance

Thermo Fisher Scientific, the world leader in serving science, today introduces the Thermo Scientific AmpSure Universal SYBR Green and Probe Master Mixes. Designed for everyday applications, the mixes support reliable, reproducible quantitative PCR (qPCR) performance and offer researchers a value-priced option as labs balance performance with budget.

ClassiX™ DNA/RNA Receives CE-IVD Marking: One Flexible, Robust Chemistry for 7 Clinical Sample Types and 9 Organism Classes

Navigating severe PCR inhibitors without dedicated kits or cold-chain logistics is now a reality. Officially CE-IVD marked, ClassiX™ DNA/RNA delivers lower Cq values than established commercial reference kits in complex matrices while consolidating manual and automated runs into a single chemistry.

Bio-Rad Expands Precision Oncology Research Portfolio for Advanced Molecular Analysis Workflows

Bio-Rad Laboratories today announced the expansion of its precision oncology research portfolio. The new assays available for use with the QX700™ ddPCR™ systems provide researchers with additional tools designed to support mutation detection research, liquid biopsy workflows, tumor-informed assay development, molecular residual disease (MRD) research, and multiplex biomarker analysis.

New KLAS Research Report Shows Clinical and Financial Impact of Ambience Healthcare at Memorial Hermann

HOPPR Expands Medical Imaging AI Portfolio with Whole-Body Musculoskeletal X-ray Narrative Model

HOPPR® FS MSK Whole-Body Narrative Model generates draft report findings from up to three X-ray views per study, with customization and integration available through HOPPR Forward Deployed Services.

START Expands its Global Early Phase Cancer Site Network into Italy Through Strategic Partnership with Istituti Fisioterapici Ospitalieri

The new START site at the IRCCS Istituto Nazionale Tumori Regina Elena will expand access to cancer clinical trials for patients in a major European oncology market.

PharmaForceIQ Launches Share of Answer Module to Evaluate and Act on AI Visibility

Share of Answer Connects AI visibility audits with prioritized actions to help biopharma teams improve how brands and disease education content are represented in AI-generated answers

Pharma Partnering US Summit 2026 Sets the Stage for New Deal-Making Conversations in Boston

Yourgene Health Insight DPYD Assay Secures TGA Regulatory Approval in Australia

• Assay enables comprehensive pharmacogenetic testing to support safer, personalised chemotherapy treatment for cancer patients • Southern Cross Diagnostics to supply IVD assay to clinical diagnostics laboratories in Australia

CluePoints Announced as Fierce Life Sciences Innovation Awards Finalist

CluePoints, a leading provider of Risk-Based Quality Management (RBQM) and clinical data quality oversight software, has been named a finalist in the Data Analytics/Business Intelligence category at the 2026 Fierce Life Sciences Innovation Awards.

Cycore Launches Unified Security, Privacy and GxP Quality Program for Life Sciences Technology Companies

Cycore Secure has launched a fixed-fee program that combines security certifications (SOC 2, ISO 27001), privacy (HIPAA, GDPR) and GxP quality management for biotech AI and SaaS companies that sell into pharma and biotech. The aim is to cut the time vendors spend clearing customer qualification audits.

Proto360 Health Launches to Help Medical Practices and Employers Standardize GLP-1 Treatment and Metabolic Care

As GLP-1 prescribing outpaces obesity medicine training, Proto360 Health gives physicians across specialties and corporate employers a dedicated care team that starts every patient with the same diagnostic assessment and uses clinical data to guide each phase of treatment.

Duet Biosystems Unveils TEMPO, a Breakthrough Platform for Combination Drug Development, at AIDDD 2026

Built on patented MuSyC technology invented at Vanderbilt University, TEMPO advances combination drug development; Duet invites pharmaceutical and biotechnology beta partners.